Floatz logo

Fingolimod

Inflammation

Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Inflammation cohort.

Asset / SponsorPhaseRating
Vildagliptin
Rio de Janeiro State University
Phase 4BB
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA
Taipei Veterans General Hospital, Taiwan
Phase 4BB
PITAVASTATIN
Aichi Gakuin University
Phase 4BB
Sitagliptin
University of Southern California
Phase 3BB
SUFENTANYL
The First Affiliated Hospital with Nanjing Medical University
Phase 4BB

View all 50 →

Same molecule, other indications

Fingolimod is also rated in:

relapsing-remitting multiple sclerosisDormant
A
Indicative ·
82 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
70 / 100
View asset →
cerebral degenerationDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →